Survival without adjuvant chemotherapy for selected patients with stage II and III nasopharyngeal carcinoma after concurrent chemoradiotherapy alone

摘要

Abstract Background The role of adjuvant chemotherapy after concurrent chemoradiotherapy (CRT) for nasopharyngeal carcinoma (NPC) is controversial. We report our phase II prospective study of withholding adjuvant chemotherapy in a subgroup of patients with American Joint Committee on Cancer (AJCC) stage II and III NPC with low risk for metastasis. Methods Between April 1998 and December 2008, 263 patients with stage II (AJCC 1997 T2aN0, T1‐T2aN1; AJCC 2010 T1N1) NPC or stage III (AJCC 1997 T1‐T2aN2; AJCC 2010 T1N2) NPC were enrolled. Patients received standard concurrent CRT with cisplatin and 5‐fluorouracil (5‐FU) but without adjuvant chemotherapy. Results With a median follow‐up of 107 months, the 5‐year overall survival (OS), disease‐free survival (DFS), and distant metastasis‐free survival (DMFS) were 92.4%, 84.4%, and 90.7% for all patients; 94.1%, 85.9%, and 92.9% for patients with stage II NPC; and 90.9%, 83.2%, and 88.9% for patients with stage III NPC, respectively. Conclusion It is safe to withhold adjuvant chemotherapy for selected patients with stage II and III NPC.